Efficacy and Safety of Donanemab for Alzheimer's Disease: A Systematic Review

Donanemab demonstrated a rapid, robust, and sustained reduction in brain amyloid plaque with no significant reaccumulation observed at 72 weeks. It was generally well-tolerated at doses up to 10 mg/kg; however, its use is associated with significant adverse effects, highlighting the need for careful risk-benefit evaluation.